---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Phase of product development"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Phase of product development. Topics: Summary: development stage and regulatory timing; Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027; Launch: Anticipated in 2028; NATiV3 topline timing: fourth quarter of 2026, as of October 2026; 14 further topics. 18 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Summary: development stage and regulatory timing

Lanifibranor is an investigational oral product in phase 3 development for adults with noncirrhotic MASH and F2 to F3 fibrosis. The last participant completed the final 72-week visit of the NATiV3 phase 3 trial, and NATiV3 topline results were expected in the fourth quarter of 2026. Inventiva states that, if the results are favorable, it anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA granted Fast Track designation and, in October 2020, Breakthrough Therapy designation, and the Chinese NMPA granted Breakthrough Therapy designation in December 2023. Company guidance for NATiV3 topline results changed across successive releases: from the second half of 2024 to the second half of 2025, the first half of 2026, the beginning of the second half of 2026, the second half of 2026, and the fourth quarter of 2026.

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf); [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf); [Inventiva first half 2022 results announcement (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-H1-2022-EN-22092022-FINAL-2-1.pdf); [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf); [Inventiva NATiV3 and financial update release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf); [Inventiva structured financing release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Project-Sulphur-EN-10-13-2024-_Version-finale.pdf); [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027

> “If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “If the results are favorable, the Company anticipates regulatory submission in the first half of 2027”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “We are on track for our anticipated top-line Phase 3 readout in the fourth quarter of 2026, followed by an anticipated regulatory filing in the first half of 2027”

Source: [Inventiva debt and equity financing release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Debt-and-Equity-EN-06-02-2026.pdf)

> “If the results are positive and subject to regulatory approval, we target the potential NDA submission for the first half of 2027, with a view to potential commercialization in 2028.”
> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “If the data from our ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH are positive, we intend to seek approval under the FDA’s accelerated approval pathway and the European Commission’s conditional authorization pathway.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-3"></a>

### Launch: Anticipated in 2028

> “is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “is preparing for a potential U.S. launch of lanifibranor in 2028, subject to FDA approval.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-2.1.1-4"></a>

### NATiV3 topline timing: fourth quarter of 2026, as of October 2026

> “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

> “Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

> “In alignment with the careful sequencing of our clinical and operational milestones, we are refining our expected data readout to the fourth quarter of 2026.”

Source: [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

<a id="topic-2.1.1-5"></a>

### NATiV3 last patient visit, September 2026

> “today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for the treatment of patients with MASH with moderate and advanced fibrosis.”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-2.1.1-6"></a>

### Approval status: not approved by any regulatory authority

> “Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.1-7"></a>

### Accelerated approval and conditional authorization: completion of the trial required for full approval

> “We may seek accelerated approval from the FDA and conditional authorization from the European Commission if our NATiV3 Phase 3 clinical trial of lanifibranor in MASH is successful at the 72-week endpoint but, even if granted, accelerated approval and conditional authorization require completion of the trial to obtain full approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-8"></a>

### Planned phase 3 outcome trial in MASH with compensated cirrhosis

> “Under the new trial design, the originally-planned Part 2 of the NATiV3 trial, a clinical outcome trial that was planned to be conducted in approximately 2,000 patients with F2 and F3 fibrosis for a maximum period of seven years, will be replaced by a placebo-controlled Phase 3 outcome trial which will be event driven and is expected to last approximately three years, depending on patient enrollment.”
> “If the results of the outcome trial in patients with MASH and compensated cirrhosis confirm sufficient clinical benefit, we anticipate the results will be used in our planned submission of an NDA to the FDA for full approval and the potential expansion of the addressable patient population beyond patients with F2 and F3 fibrosis to include patients with MASH and compensated cirrhosis”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-9"></a>

### FDA Fast Track designation for NASH, September 2019

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH).”

Source: [Inventiva Fast Track designation release (2019)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-FDA-Fast-Track-EN-26092019-VF.pdf)

<a id="topic-2.1.1-10"></a>

### FDA Breakthrough Therapy designation for NASH, October 2020

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to lanifibranor, the Company’s lead drug candidate, for the treatment of NASH.”
> “The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients.”

Source: [Inventiva Breakthrough Therapy designation release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-Breakthrough-Therapy-Designation-EN-12-10-20.pdf)

> “The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.1-11"></a>

### FDA Fast Track designation extended to NASH with compensated cirrhosis, September 2021

> “today announced that the U.S. Food and Drug Administration (FDA) has decided that the Fast Track designation previously granted to lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis.”

Source: [Inventiva Fast Track compensated cirrhosis release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Fast-Track-EN-21092021.pdf)

<a id="topic-2.1.1-12"></a>

### China NMPA Breakthrough Therapy designation for MASH, December 2023

> “Based on the results from the Phase 2b NATIVE clinical trial, lanifibranor was granted Breakthrough Therapy Designation for MASH by the U.S. Food and Drug Administration in October 2020 and by the Chinese National Medical Products Administration (NMPA) in December 2023.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

> “In December 2023, we announced that our licensee CTTQ, who joined our NATiV3 trial, randomized the first patient in China and that lanifibranor was granted Breakthrough Therapy Designation for MASH by the Chinese NMPA.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-13"></a>

### EU PRIME designation

No evidence found.

<a id="topic-2.1.1-14"></a>

### Development in China and Japan: regulatory approval in China to rest on NATiV3; pivotal trial in Japan and South Korea after NATiV3 results

> “CTTQ joined Inventiva’s ongoing NATiV3 pivotal Phase 3 clinical trial, which includes over 60 sites across mainland China.”
> “Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

> “In 2025, Hepalys conducted a Phase 1 trial of lanifibranor in Japan. The results of this Phase 1 trial were positive and are expected to support the initiation of a dedicated pivotal trial in patients with MASH in the Hepalys Territory, which is planned to start once the results of NATiV3 are available.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.1-15"></a>

### NATiV3 topline timing, September 2021, superseded in September 2022

> “The last visit of the last patient enrolled in part 1 of the NATiV3 Phase III clinical trial is planned for the first half of 2024, with the publication of the topline results of part 1 of the trial expected for the second half of 2024.”
> “If part 1 of the NATiV3 trial is successful, Inventiva intends to seek accelerated approval in the United States and conditional approval in the EU for lanifibranor.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-2.1.1-16"></a>

### NATiV3 topline timing, September 2022, superseded in December 2023

> “Accordingly, the publication of the topline results of the part 1 of NATiV3 is now targeted for second half of 2025.”

Source: [Inventiva first half 2022 results announcement (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-H1-2022-EN-22092022-FINAL-2-1.pdf)

<a id="topic-2.1.1-17"></a>

### NATiV3 topline timing, December 2023, superseded in July 2024

> “Topline results for the Phase III NATiV3 clinical trial are now expected to be published in the first half of 2026 versus the second half of 2025, as previously communicated.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-2.1.1-18"></a>

### NATiV3 topline timing, July 2024, superseded in October 2024

> “First visit of the last patient of NATiV3 is anticipated to occur during the second half of 2024, and topline results are expected at the beginning of the second half of 2026.”

Source: [Inventiva NATiV3 and financial update release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-and-fiancial-situation-updates-EN-07-05-2024.pdf)

<a id="topic-2.1.1-19"></a>

### NATiV3 topline timing, October 2024 to November 2025, superseded in March 2026

> “The Company also estimates that, prior to the Transaction, it would need approximately €250 million to finance its activities until the topline results from its NATiV3 trial, targeted for the second half of 2026.”

Source: [Inventiva structured financing release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Project-Sulphur-EN-10-13-2024-_Version-finale.pdf)

> “Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval”
> “Topline results of NATiV3 are expected in the second half of 2026.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

> “Topline results of NATiV3 – expected in the second half of 2026”

Source: [Inventiva third quarter 2025 results announcement (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Q3-2025-CA-Cash-EN-11-21-2025.pdf)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
